Using Noninvasive Electrophysiology to Determine Time Windows of Neuroprotection in Optic Neuropathies.
glaucoma
neuroprotection
optic neuropathy
pattern electroretinogram
retinal ganglion cells
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
20 May 2022
20 May 2022
Historique:
received:
26
04
2022
revised:
12
05
2022
accepted:
13
05
2022
entrez:
28
5
2022
pubmed:
29
5
2022
medline:
1
6
2022
Statut:
epublish
Résumé
The goal of neuroprotection in optic neuropathies is to prevent loss of retinal ganglion cells (RGCs) and spare their function. The ideal time window for initiating neuroprotective treatments should be the preclinical period at which RGCs start losing their functional integrity before dying. Noninvasive electrophysiological tests such as the Pattern Electroretinogram (PERG) can assess the ability of RGCs to generate electrical signals under a protracted degenerative process in both clinical conditions and experimental models, which may have both diagnostic and prognostic values and provide the rationale for early treatment. The PERG can be used to longitudinally monitor the acute and chronic effects of neuroprotective treatments. User-friendly versions of the PERG technology are now commercially available for both clinical and experimental use.
Identifiants
pubmed: 35628564
pii: ijms23105751
doi: 10.3390/ijms23105751
pmc: PMC9145583
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : NIH HHS
ID : RO1 EY019077
Pays : United States
Organisme : NIH HHS
ID : RO1 EY014957
Pays : United States
Organisme : NIH HHS
ID : R24 EY028785
Pays : United States
Organisme : NIH HHS
ID : P30-EY014801
Pays : United States
Organisme : Research to Prevent Blindness
ID : Unrestricted Grant to Bascom Palmer Eye Institute
Références
Invest Ophthalmol Vis Sci. 2013 Mar 28;54(3):2346-52
pubmed: 23412088
Vision Res. 2009 Mar;49(5):505-13
pubmed: 19124035
Am J Ophthalmol. 2022 Mar 7;:
pubmed: 35271811
Cells. 2021 Jun 05;10(6):
pubmed: 34198840
Transl Vis Sci Technol. 2022 Mar 2;11(3):31
pubmed: 35344016
J Glaucoma. 2017 May;26(5):459-465
pubmed: 28263259
Exp Eye Res. 2016 Apr;145:68-74
pubmed: 26614910
Prog Retin Eye Res. 2005 Mar;24(2):183-215
pubmed: 15610973
J Glaucoma. 2014 Oct-Nov;23(8):494-500
pubmed: 23429613
Natl Sci Rev. 2019 Jul;6(4):775-785
pubmed: 34691933
Am J Ophthalmol. 2005 Sep;140(3):407-15
pubmed: 16083844
Eye (Lond). 2004 Nov;18(11):1089-95
pubmed: 15534594
Cold Spring Harb Perspect Biol. 2012 Jan 01;4(1):a005736
pubmed: 22086977
Invest Ophthalmol Vis Sci. 2014 Apr 17;55(4):2469-75
pubmed: 24667861
J Neuroophthalmol. 2012 Dec;32(4):354-8
pubmed: 23196946
Front Immunol. 2020 Sep 10;11:2021
pubmed: 33013859
Proc Natl Acad Sci U S A. 2004 Apr 6;101(14):5123-8
pubmed: 15051886
Front Neurol. 2021 May 24;12:662838
pubmed: 34108929
Sci Rep. 2019 Dec 5;9(1):18396
pubmed: 31804570
Neural Plast. 2016;2016:4842159
pubmed: 26925270
Exp Eye Res. 2015 Dec;141:164-70
pubmed: 25998495
Neural Regen Res. 2020 Dec;15(12):2237-2238
pubmed: 32594035
Invest Ophthalmol Vis Sci. 2005 Apr;46(4):1296-302
pubmed: 15790894
Ophthalmology. 2009 Dec;116(12):2271-6
pubmed: 19854514
J Physiol. 2008 Sep 15;586(18):4377-84
pubmed: 18617564
Semin Ophthalmol. 1998 Dec;13(4):178-88
pubmed: 9878668
Evol Med Public Health. 2016 May 21;2016(1):170-6
pubmed: 27121451
Vis Neurosci. 2005 Sep-Oct;22(5):637-48
pubmed: 16332275
Invest Ophthalmol Vis Sci. 2012 Feb 13;53(2):659-63
pubmed: 22247462
Biochim Biophys Acta Mol Basis Dis. 2020 Jun 1;1866(6):165743
pubmed: 32105823
J Neurol Sci. 2012 Nov 15;322(1-2):187-91
pubmed: 22749004
Invest Ophthalmol Vis Sci. 2013 Mar 28;54(3):1898-904
pubmed: 23422821
Eye (Lond). 2022 Apr;36(4):818-826
pubmed: 33911213
Eye (Lond). 2004 Nov;18(11):1075-84
pubmed: 15534592
N Engl J Med. 2009 Oct 15;361(16):1570-83
pubmed: 19828534
Asia Pac J Ophthalmol (Phila). 2018 Jul-Aug;7(4):246-250
pubmed: 30066502
Sci Transl Med. 2012 Sep 12;4(151):151ps15
pubmed: 22972841
Prog Retin Eye Res. 2022 Jan;86:100976
pubmed: 34102318
Neurol Sci. 2011 Jun;32(3):433-41
pubmed: 21409508
Prog Brain Res. 2008;173:437-50
pubmed: 18929126
Int Rev Neurobiol. 2012;105:1-17
pubmed: 23206593
Invest Ophthalmol Vis Sci. 2007 Oct;48(10):4573-9
pubmed: 17898280
Science. 2017 Feb 17;355(6326):756-760
pubmed: 28209901
Clin Neurophysiol. 2013 Aug;124(8):1652-8
pubmed: 23571090
BMC Genet. 2007 Jul 03;8:45
pubmed: 17608931
J Neurosci. 2009 Oct 14;29(41):12776-86
pubmed: 19828789
Electroencephalogr Clin Neurophysiol. 1998 Jan;108(1):73-9
pubmed: 9474064
Clin Exp Ophthalmol. 2012 May-Jun;40(4):350-7
pubmed: 22697056
J Cell Biol. 2007 Dec 31;179(7):1523-37
pubmed: 18158332
J Glaucoma. 2013 Mar;22(3):255-64
pubmed: 22138883
Can J Ophthalmol. 2007 Jun;42(3):403-8
pubmed: 17508035
Transl Vis Sci Technol. 2017 May 22;6(3):5
pubmed: 28553559
Nutrients. 2020 Jun 27;12(7):
pubmed: 32605122
Curr Eye Res. 2020 Mar;45(3):327-338
pubmed: 31475591
Invest Ophthalmol Vis Sci. 2013 Feb 01;54(2):1236-43
pubmed: 23307964
J Neurosci. 2021 Jan 20;41(3):435-445
pubmed: 33234610
Eye (Lond). 2000 Jun;14 ( Pt 3B):464-72
pubmed: 11026975
Annu Rev Vis Sci. 2017 Sep 15;3:91-120
pubmed: 28731838
Invest Ophthalmol Vis Sci. 2000 Oct;41(11):3460-6
pubmed: 11006239
Mol Vis. 2010 Dec 31;16:2939-47
pubmed: 21203347
Invest Ophthalmol Vis Sci. 2007 Oct;48(10):4564-72
pubmed: 17898279